vTv Therapeutics to Participate in Upcoming Canaccord Genuity and Solebury Trout Conferences
August 06 2019 - 4:05PM
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage
biopharmaceutical company engaged in the discovery and development
of orally administered treatments for diabetes and Alzheimer’s
disease, today announced that it will be participating in the
following conferences:
- Canaccord Genuity’s 39th Annual Growth
Conference on August 7-8, 2019 in Boston, MA. vTv
management will present a corporate and clinical overview at 4:30pm
ET on Wednesday, August 7, 2019 in the Toronto Room at the
InterContinental Hotel in Boston. A live webcast of the
presentation can be accessed here and will be archived for 30 days
following the presentation at www.vTvTherapeutics.com.
- Solebury Trout’s 9th Annual Hamptons CEO Roundtable
Conference on Thursday, August 15, 2019 in Bridgehampton,
NY.
About vTv Therapeutics
vTv Therapeutics Inc. is a public, clinical-stage
biopharmaceutical company engaged in the discovery and development
of orally administered small molecule drug candidates to fill
significant unmet medical needs. vTv has a pipeline of clinical
drug candidates led by programs for the treatment of diabetes,
Alzheimer’s disease, and inflammatory disorders.
Forward-Looking Statements
This release contains forward-looking statements, which involve
risks and uncertainties. These forward-looking statements can be
identified by the use of forward-looking terminology, including the
terms “anticipate,” “believe,” “could,” “estimate,” “expect,”
“intend,” “may,” “plan,” “potential,” “predict,” “project,”
“should,” “target,” “will,” “would” and, in each case, their
negative or other various or comparable terminology. All statements
other than statements of historical facts contained in this
release, including statements regarding the timing of our clinical
trials, our strategy, future operations, future financial position,
future revenue, projected costs, prospects, plans, objectives of
management and expected market growth are forward-looking
statements. These statements involve known and unknown risks,
uncertainties and other important factors that may cause our actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied by the forward-looking statements. Important factors that
could cause our results to vary from expectations include those
described under the heading “Risk Factors” in our Annual Report on
Form 10-K and our other filings with the SEC. These
forward-looking statements reflect our views with respect to future
events as of the date of this release and are based on assumptions
and subject to risks and uncertainties. Given these uncertainties,
you should not place undue reliance on these forward-looking
statements. These forward-looking statements represent our
estimates and assumptions only as of the date of this release and,
except as required by law, we undertake no obligation to update or
review publicly any forward-looking statements, whether as a result
of new information, future events or otherwise after the date of
this release. We anticipate that subsequent events and developments
will cause our views to change. Our forward-looking statements do
not reflect the potential impact of any future acquisitions,
merger, dispositions, joint ventures or investments we may
undertake. We qualify all of our forward-looking statements by
these cautionary statements.
ContactsInvestors: vTv Therapeutics Inc.
IR@vtvtherapeutics.com
or Media:Josh Vlasto212-572-5969PR@vtvtherapeutics.com
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Mar 2024 to Apr 2024
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Apr 2023 to Apr 2024